Fmoc-MMAE

Fmoc-MMAE is a protective group-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Fmoc-MMAE can be used in the synthesis of ADC[1].

Product Specifications

CAS Number

[474645-26-6]

UNSPSC

12352203

Hazard Statement

H302, H315, H319, H335

Target

ADC Payload; Microtubule/Tubulin

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/fmoc-mmae.html

Purity

99.60

Solubility

DMSO : ≥ 45 mg/mL

Smiles

CC[C@H](C)[C@@H]([C@@H](CC(N1[C@@H](CCC1)[C@@H]([C@@H](C)C(N[C@H](C)[C@@H](O)C2=CC=CC=C2)=O)OC)=O)OC)N(C([C@H](C(C)C)NC([C@H](C(C)C)N(C(OCC3C4=C(C=CC=C4)C5=C3C=CC=C5)=O)C)=O)=O)C

Molecular Formula

C54H77N5O9

Molecular Weight

940.22

Precautions

H302, H315, H319, H335

References & Citations

[1]Pan D, et al. An antibody-drug conjugate targeting a GSTA glycosite-signature epitope of MUC1 expressed by non-small cell lung cancer. Cancer Med. 2020;9 (24) :9529-9540.